{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:58:09Z","timestamp":1790816289650,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jaad.2014.07.033","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T18:09:52Z","timestamp":1421086192000},"page":"221-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Cutaneous adverse effects of targeted therapies"],"prefix":"10.1016","volume":"72","author":[{"given":"James B.","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren E.","family":"Golitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.07.033_bib1","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical\u00a0effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.033_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies\u00a0in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2014.07.033_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in\u00a0BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.07.033_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib9","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/bjd.12555","article-title":"Acute kidney injury in patients with severe rash\u00a0on vemurafenib treatment for metastatic melanomas","volume":"169","author":"Regnier-Rosencher","year":"2013","journal-title":"Br\u00a0J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib15","unstructured":"Datapharm web site. Roche, Zelboraf 240 mg film-coated tablets. Summary of product characteristics. Available at:\u00a0http:\/\/www.medicines.org.uk\/EMC\/medicine\/26056\/SPC\/Zelboraf+240+mg+Film-coated+Tablets\/. Accessed August 24, 2014."},{"key":"10.1016\/j.jaad.2014.07.033_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2014.07.033_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib20","first-page":"ra30","article-title":"BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling","volume":"7","author":"Sanchez-Laorden","year":"2014","journal-title":"Sci\u00a0Signal"},{"key":"10.1016\/j.jaad.2014.07.033_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side\u00a0effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib24","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamadermatol.2013.2023","article-title":"Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib","volume":"149","author":"Falchook","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2011.38.2895","article-title":"Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?","volume":"30","author":"Lacouture","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/DAD.0b013e3182604873","article-title":"Squamoproliferative lesions arising in the setting of BRAF inhibition","volume":"34","author":"Harvey","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2014.07.033_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2133.2011.10744.x","article-title":"Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development","volume":"166","author":"Siegel","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib31","first-page":"521","article-title":"Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome","volume":"164","author":"Siegel","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib32","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib33","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.07.033_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/jid.2012.268","article-title":"Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma","volume":"133","author":"Viros","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamadermatol.2013.2583","article-title":"A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil","volume":"149","author":"LaPresto","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib36","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","article-title":"Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib","volume":"30","author":"Anforth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjd.12659","article-title":"Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids","volume":"170","author":"Sachse","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/bjd.12519","article-title":"Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors","volume":"169","author":"Anforth","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","article-title":"Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma","volume":"148","author":"Alloo","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib41","first-page":"7","article-title":"A case of vemurafenib-induced keratosis pilaris-like eruption","volume":"18","author":"Wang","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2014.07.033_bib42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/2013.jamadermatol.23","article-title":"Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib","volume":"148","author":"Ma","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.critrevonc.2013.06.002","article-title":"Cutaneous toxicities of\u00a0BRAF inhibitors: clinical and pathological challenges and\u00a0call to action","volume":"88","author":"Mandala","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2014.07.033_bib44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/exd.12119","article-title":"Vemurafenib: an unusual UVA-induced photosensitivity","volume":"22","author":"Gelot","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cup.12149","article-title":"Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib","volume":"40","author":"Kim","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2014.07.033_bib47","first-page":"16","article-title":"Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect\u00a0of variable severity","volume":"19","author":"Maldonado-Seral","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2014.07.033_bib48","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1200\/JCO.2012.45.8307","article-title":"Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib","volume":"31","author":"Sinha","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","article-title":"Vemurafenib-induced neutrophilic panniculitis","volume":"22","author":"Monfort","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2014.07.033_bib50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archdermatol.2012.2649","article-title":"Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy","volume":"148","author":"Haenssle","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib52","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/bjd.12210","article-title":"Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy","volume":"168","author":"Debarbieux","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib53","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.12093","article-title":"Second primary melanomas on treatment with vemurafenib","volume":"168","author":"Dalle","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib54","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib55","doi-asserted-by":"crossref","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2014.07.033_bib56","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/jid.2013.462","article-title":"Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy","volume":"134","author":"Perier-Muzet","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib57","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archdermatol.2012.758","article-title":"Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption","volume":"148","author":"Gupta","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib58","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","article-title":"Vemurafenib and radiosensitization","volume":"149","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1684\/ejd.2013.2193","article-title":"Severe radiotherapy-induced extracutaneous toxicity under vemurafenib","volume":"23","author":"Peuvrel","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib60","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","article-title":"Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy","volume":"31","author":"Satzger","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dth.12027","article-title":"Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4","volume":"26","author":"Fischer","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.07.033_bib62","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/cup.12199","article-title":"Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma","volume":"40","author":"Clarke","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2014.07.033_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of\u00a0combination chemotherapy with BRAF and MEK inhibitors:\u00a0a report of two cases","volume":"169","author":"Green","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib64","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"Davies","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jaad.2014.07.033_bib65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","article-title":"The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth\u00a0arrest in melanoma cells and tumor regression when combined with docetaxel","volume":"14","author":"Haass","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.033_bib66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1535-7163.MCT-06-0436","article-title":"Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jaad.2014.07.033_bib67","first-page":"1649","article-title":"Synchronous\u00a0BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity","volume":"6","author":"Gadiot","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jaad.2014.07.033_bib68","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib69","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib70","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.033_bib71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib72","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2014.07.033_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/02841860903104152","article-title":"Case\u00a0studies showing clinical signs and management of cutaneous toxicity of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours","volume":"49","author":"Desar","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib74","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase kinase\u00a0inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.033_bib75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT\u00a0pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib76","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.07.033_bib77","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/sj.bjc.6604637","article-title":"A novel AKT3 mutation in melanoma tumours and cell lines","volume":"99","author":"Davies","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","article-title":"The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis","volume":"48","author":"Gomez-Fernandez","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib80","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","article-title":"mTOR inhibitor-associated dermatologic and mucosal problems","volume":"24","author":"Campistol","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaad.2014.07.033_bib82","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1600-6143.2006.01678.x","article-title":"Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus","volume":"7","author":"Chuang","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaad.2014.07.033_bib83","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.07.033_bib84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","article-title":"The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents","volume":"4","author":"Sankhala","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib85","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.3816\/CGC.2009.n.019","article-title":"Eosinophilic rash secondary to temsirolimus","volume":"7","author":"Gandhi","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib86","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1002\/cncr.27505","article-title":"Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors","volume":"118","author":"Balagula","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib87","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib88","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib89","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib90","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.ki.5002116","article-title":"Sirolimus-associated chronic pyogenic periungual infection","volume":"71","author":"Raju","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaad.2014.07.033_bib91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse\u00a0events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"Mah\u00e9","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2014.07.033_bib92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000329902","article-title":"Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors","volume":"223","author":"De Masson","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.07.033_bib93","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib94","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib95","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00007890-200209150-00025","article-title":"Sirolimus-induced leukocytoclastic vasculitis","volume":"74","author":"Hardinger","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2014.07.033_bib96","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib97","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting\u00a0the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib98","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.12840","article-title":"Multiple highly and moderately differentiated squamous cell carcinomas of the skin during Vismodegib treatment of inoperable basal cell carcinoma","volume":"171","author":"Orouji","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development\u00a0of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib102","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1016\/j.jaad.2014.07.033_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib104","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/oxfordjournals.annonc.a058986","article-title":"Minoxidil (Mx) as a prophylaxis of doxorubicin\u2013induced alopecia","volume":"5","author":"Rodriguez","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib105","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1073\/pnas.0607399104","article-title":"Wnt signaling interacts with Shh to regulate taste papilla development","volume":"104","author":"Iwatsuki","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2014.07.033_bib106","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ydbio.2004.07.042","article-title":"Sonic hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development","volume":"276","author":"Liu","year":"2004","journal-title":"Dev Biol"},{"key":"10.1016\/j.jaad.2014.07.033_bib107","first-page":"58","article-title":"Taste and odor abnormalities in cancer patients","volume":"7","author":"Hong","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib108","first-page":"68","article-title":"Taste and smell alterations in cancer patients\u2014real problems with few solutions","volume":"7","author":"Halyard","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib109","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ijrobp.2006.10.046","article-title":"Does zinc sulfate prevent\u00a0therapy-induced taste alterations in head and neck\u00a0cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)","volume":"67","author":"Halyard","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2014.07.033_bib110","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1188\/12.CJON.E173-E177","article-title":"Pilot study of \u201cmiracle fruit\u201d to\u00a0improve food palatability for patients receiving chemotherapy","volume":"16","author":"Wilken","year":"2012","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.jaad.2014.07.033_bib111","first-page":"155","article-title":"Radiochemotherapy with amifostine cytoprotection for head and neck cancer","volume":"6","author":"B\u00fcntzel","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.07.033_bib112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib113","first-page":"475","article-title":"Side effects of systemic oncological therapies in dermatology","volume":"10","author":"Zimmer","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.07.033_bib114","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib116","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00281-011-0247-y","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"33","author":"Krauze","year":"2011","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaad.2014.07.033_bib117","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","article-title":"Vitiligo in patients with metastatic melanoma: a\u00a0good prognostic sign","volume":"9","author":"Nordlund","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.033_bib118","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2014.07.033_bib119","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib121","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.033_bib122","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.033_bib123","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214017642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214017642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:34Z","timestamp":1759271614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214017642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0190962214017642"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.07.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse effects of targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(14)02282-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}